<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458393</url>
  </required_header>
  <id_info>
    <org_study_id>CO-US-104-0288</org_study_id>
    <secondary_id>10445</secondary_id>
    <secondary_id>1U01AI064002</secondary_id>
    <secondary_id>iPrEx</secondary_id>
    <nct_id>NCT00458393</nct_id>
    <nct_alias>NCT00350324</nct_alias>
  </id_info>
  <brief_title>Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men</brief_title>
  <acronym>iPrEx</acronym>
  <official_title>Chemoprophylaxis for HIV Prevention in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether daily use of emtricitabine/tenofovir
      disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV
      counseling, condoms, and treatment for other sexually transmitted infections (STIs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Joint United Nations Programme on AIDS estimates that 14,000 persons are newly infected
      with HIV every day worldwide; one half of these infections occur in people between the ages
      of 15 and 24. New infections occur despite widespread awareness of the modes of HIV
      transmission and the protection afforded by condom use. Effective interventions for HIV
      prevention are urgently needed. This study will evaluate the safety and efficacy of
      chemoprophylaxis for HIV prevention in men who have sex with men (MSM) who are at high risk
      for HIV infection despite using condoms, receiving HIV counseling, and receiving treatment
      for STIs, particularly hepatitis B virus (HBV) infection. A daily combination dose of
      emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) has been selected for evaluation
      because it has a well-established safety record in previous studies and was demonstrated to
      be effective for HIV prevention in primate models. These medications have long half-lives
      that allow daily dosing and do not have known interactions with hormonal contraception,
      methadone, or tuberculosis therapies.

      Once on the study drug, participants will be followed for a variable length of time, starting
      within 4 weeks of their screening visit and lasting up to 144 weeks. All participants will be
      followed for at least 8 weeks after stopping study drug. Participants who are reactive to a
      Hepatitis B surface antigen (HBsAg) test will be followed for hepatic flares for 16
      additional weeks for a total of 24 weeks after stopping study drug. If enrolled in the
      optional substudy of bone mineral density, fat distribution, and fasting lipids, the
      participant will be asked to return for one additional visit 24 weeks after stopping study
      drug. Participants who HIV seroconvert during their participation will also be followed until
      the end of the study.

      All study visits will be at 4 week intervals. At study entry, high risk, HIV uninfected MSM
      will be randomly assigned to receive either daily FTC/TDF or placebo, in addition to standard
      HIV counseling, condoms, and sexually transmitted infection (STI) management. The study will
      closely monitor biological and behavioral safety, including careful analysis of drug
      resistance, kidney and liver function, and risk behavior.

      At the screening visit, participants will undergo HIV antibody and HBV testing, a medical
      history, a medical exam, blood and urine collection, risk behavior assessment, and STI
      testing. At study entry, participants will be given study medication; tested for HCV; and
      offered the HBV vaccine, if applicable. At all study visits, there will be HIV antibody
      testing, pill counts, adherence checks, study medication distribution, HIV counseling, and
      condom distribution. A medical history and blood will be taken on selected visits, along with
      STI testing and treatment if needed. Testing and treatment of STIs will be provided at no
      cost to the participant.

      All study participants will be encouraged to join a substudy that will assess interactions
      between HBV infection, bone mineral density and fat distribution, and immune function. If
      enrolled in the substudy, the participant will be asked to return for one additional visit 24
      weeks after stopping the study medication. All participants in the substudy will undergo dual
      energy x-ray absorptiometry (DEXA) scans, and HIV infected participants will undergo
      additional blood collection.

      Sites will have the option of participating in the following four substudies:

      The Hair Substudy: Participants who are receiving FTC/TDF will be eligible to enroll. At each
      12-week follow-up study visit, hair samples will be collected and questionnaires will be
      completed.

      The Urine Substudy: For all participants who elect to enroll in this substudy, additional
      testing will occur on blood and urine samples collected at each 24-week follow-up visit. An
      additional urine collection will occur 8 weeks after participants stop receiving FTC/TDF.

      The Semen Substudy: Participants who seroconvert during the study may elect to participate in
      this substudy. One semen sample will be collected at participants' next study visit when
      plasma viral load testing is performed.

      The Gonorrhea and Chlamydia Substudy: Participants in this substudy will undergo rectal and
      oropharyngeal swab procedures and urine collection at the 24-week study visit.

      After the randomized phase ends, if the daily oral FTC/TDF arm is shown to be beneficial and
      safe, participants will be given the option of participating in an open label extension
      phase. During this extension phase, study participants will receive daily oral open-label
      FTC/TDF, in addition to standard counseling, condoms, and STI management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Seroconversion</measure>
    <time_frame>Monthly follow-up through a median of 1.2 years</time_frame>
    <description>Confirmed HIV infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 1 or Higher Creatinine Toxicity</measure>
    <time_frame>Duration of follow-up, median 1.2 years</time_frame>
    <description>Creatinine which reach grade 1 (mild, 1.1 to 1.3 local upper limit of normal) or higher by the US Division of AIDS grading table (version 1) or a 50% increase in creatinine from the baseline value. The DAIDS table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 or Higher Phosphorous Toxicity</measure>
    <time_frame>The entire follow-up period, median 1.2 years</time_frame>
    <description>Grade 3 or higher phosphorous toxicity (hypophosphatemia) by the Division of AIDS Grading Table (severe, level at or below 1.9 mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 2, 3, or 4 Laboratory Adverse Events</measure>
    <time_frame>Entire follow-up, median 1.2 years</time_frame>
    <description>Number of participants with at least one Grade 2, 3, or 4 laboratory adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 2, 3, or 4 Clinical Adverse Events</measure>
    <time_frame>Entire follow-up, median 1.2 years</time_frame>
    <description>Number of participants with at least 1 Grade 2, 3, or 4 clinical adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis Flares Among Hepatitis B Virus (HBV) Infected Persons During and After Chemoprophylaxis</measure>
    <time_frame>Quarterly lab tests through a median follow-up of 1.2 years</time_frame>
    <description>A hepatic flare is defined as an increase in alanine transaminase or aspartate transaminase to &gt;5 fold upper limit of normal at any visit, or an increase to &gt;2.5 fold upper limit of normal for 3 months, within 24 weeks of permanently stopping study drug.
More details in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752387/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Bone Mineral Density</measure>
    <time_frame>baseline and week 24.</time_frame>
    <description>% Change from baseline in bone mineral density (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in in hip and L1-L4 spine by dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Body Fat</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Body Fat from Baseline by dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Fasting Triglycerides</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage Change (Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Triglycerides from Baseline from a fasting sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percent change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in fasting total cholesterol from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load Among HIV Infected Participants</measure>
    <time_frame>At the time closest to HIV detection</time_frame>
    <description>HIV-RNA in log10 units among HIV infected participants at the time closest to HIV detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Among HIV Infected Participants Drug Resistance</measure>
    <time_frame>at the time of HIV acquisition</time_frame>
    <description>Genotypic resistance by clinical assays among the seroconverters from baseline to the end of the study treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Count Among HIV Infected Participants</measure>
    <time_frame>at the time infection was detected</time_frame>
    <description>CD4 cell count for HIV infected participants during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Missed Doses by Pill Count</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Estimated proportion of missed doses by pill count (assuming pills taken in unreturned bottles)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Missed Doses by Estimate During CASI Interview</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of missed doses by estimate during computer assisted structured interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Condomless Sexual Partners With HIV Positive or Unknown Status</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Participants self-report of the number of sexual partners with HIV positive or unknown status in the previous 12 weeks with whom they had condomless anal sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Sexual Partners</measure>
    <time_frame>24 weeks</time_frame>
    <description>Self-reported total number of sexual partners in the previous 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status.</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Self-reported condomless receptive anal intercourse in the previous 12 weeks with any partners regardless of status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Confirmed Syphilis During Follow-Up</measure>
    <time_frame>All Follow-Up median of 1.2 years of follow-up</time_frame>
    <description>Number of participants who have at least 1 confirmed syphilis infection during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HSV-2 During the Follow-up Period</measure>
    <time_frame>Total study follow-up, a median of 1.2 years</time_frame>
    <description>Incidence of HSV-2 during the follow-up period among those HIV-2 negative at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of Gonorrhea During the Follow-up Period</measure>
    <time_frame>All of follow-up period, median of 1.2 years</time_frame>
    <description>Diagnosis of gonorrhea during the follow-up period by PCR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2499</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>TDF/FTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug. Daily oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daily TDF/FTC</intervention_name>
    <description>daily oral medication</description>
    <arm_group_label>TDF/FTC</arm_group_label>
    <other_name>truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>daily oral medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex (at birth)

          -  HIV uninfected

          -  Age having reached the local age of consent

          -  High risk for HIV infection including any of the following: 1) No condom use during
             anal intercourse with a male HIV-positive partner or a male partner of unknown HIV
             status during the last 6 months; (2) anal intercourse with more than 3 male sex
             partners during the last 6 months; (3) exchange of money, gifts, shelter, or drugs for
             anal sex with a male partner during the last 6 months; (4) sex with a male partner and
             STI diagnosis during the last 6 months or at screening, or (5) sexual partner of an
             HIV-infected man with whom condoms are not consistently used in the last 6 months.

          -  Able to provide a street address of residence for themselves and one personal contact
             who would know their whereabouts during the study period

          -  Healthy enough to work, as indicated by score of 80 or greater on the Karnofsky scale

          -  Certain laboratory values

          -  A urine dipstick with a negative or trace result for both glucose and protein within
             28 days of enrollment.

          -  Ability to understand and local language for which an informed consent form has been
             approved by a local IRB and registered with the study sponsor.

        Inclusion Criteria for Open-Label Extension:

          -  Participated in a randomized, placebo-controlled, PrEP trail

          -  Has been unblinded

          -  Has provided informed consent

        Exclusion Criteria:

          -  Previously diagnosed active and serious infections, including tuberculosis infection,
             osteomyelitis, or infections requiring parenteral antibiotic therapy

          -  Active clinically significant medical problems including heart disease (e.g., symptoms
             of ischemia, congestive heart failure, arrhythmia), lung disease (steroid-dependent
             chronic obstructive pulmonary disease), diabetes requiring hypoglycemic medication, or
             previously diagnosed cancer expected to require further treatment

          -  Acute HBV infection at the screening visit or presence of treatment indications for
             hepatitis B based on local practice standards; or clinical signs of hepatic cirrhosis

          -  History of pathological bone fractures not related to trauma

          -  Receiving ongoing therapy with certain HIV/AIDS-related medications or other
             medications as determined by the investigator

          -  Definitely or possibly received an anti-HIV vaccine while participating in a blinded
             clinical trial

          -  Current alcohol or drug use that, in the opinion of the investigator, may interfere
             with the study

          -  Current participation in a clinical trial or cohort study other than sub-studies of
             this protocol

          -  Any condition at enrollment that, in the opinion of the investigator, would make
             participation in the study unsafe or would interfere with the study

          -  Sites may utilize additional criteria that restrict enrollment to a subset of people
             who meet the protocol-defined enrollment criteria.

        Exclusion Criteria for Open-Label Extension:

        - Site leadership believes participant will have difficulty completing requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M. Grant, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>J. David Gladstone Institutes, University of California San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Dept. of Public Health iPrEx CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroger Hospital of Cook County/Core Center IPREX CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health iPrEx CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPEC/FIOCRUZ iPrEx CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Projeto Praca Onze, Universidade Federal do Rio de Janeiro iPrEx CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941.590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade de Sao Paulo iPrEx CRS</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Ecuatoriana Equidad, Guayaquil, iPrEx CRS</name>
      <address>
        <city>Guayaquil</city>
        <state>Guayas</state>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociación Civil Selva Amazónica, Iquitos, iPrEx CRS</name>
      <address>
        <city>Iquitos</city>
        <state>Maynas</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Médicas en Salud (INMENSA), Lince, iPrEx CRS</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Ctr. iPrEx CRS</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Health Sciences iPrEx CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Ecuador</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1011205</url>
    <description>Primary Manuscript</description>
  </link>
  <results_reference>
    <citation>Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.</citation>
    <PMID>21091279</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2007</study_first_submitted>
  <study_first_submitted_qc>April 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <results_first_submitted>December 27, 2016</results_first_submitted>
  <results_first_submitted_qc>January 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2018</results_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Chemoprophylaxis</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Viral human hepatitis</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study recruited HIV uninfected participants whose sexual practices put them at risk for HIV infection. They were recruited from community clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TDF/FTC</title>
          <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1251"/>
                <participants group_id="P2" count="1248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="942"/>
                <participants group_id="P2" count="953"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sites marked other on the form.</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TDF/FTC</title>
          <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1251"/>
            <count group_id="B2" value="1248"/>
            <count group_id="B3" value="2499"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1158"/>
                    <measurement group_id="B2" value="1147"/>
                    <measurement group_id="B3" value="2305"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B2" value="24" lower_limit="18" upper_limit="63"/>
                    <measurement group_id="B3" value="24" lower_limit="18" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male Sex at Birth. Identify Trans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male Sex at Birth. Identify Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male Sex at Birth. Identify Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1081"/>
                    <measurement group_id="B2" value="1079"/>
                    <measurement group_id="B3" value="2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ecuador</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="700"/>
                    <measurement group_id="B2" value="700"/>
                    <measurement group_id="B3" value="1400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV Seroconversion</title>
        <description>Confirmed HIV infection</description>
        <time_frame>Monthly follow-up through a median of 1.2 years</time_frame>
        <population>Excludes participants who were HIV+ at enrollment (2 TDF/FTC, 8 Placebo) and those with no follow-up HIV test (25 TDF/FTC and 22 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Seroconversion</title>
          <description>Confirmed HIV infection</description>
          <population>Excludes participants who were HIV+ at enrollment (2 TDF/FTC, 8 Placebo) and those with no follow-up HIV test (25 TDF/FTC and 22 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1224"/>
                <count group_id="O2" value="1218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary null hypothesis: Relative hazard of 0.7 or less. Secondary null hypothesis: Relative hazard of 1.0 or less.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>secondary p-value given.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>stratified by site</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.577</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.105</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.404</ci_lower_limit>
            <ci_upper_limit>.824</ci_upper_limit>
            <estimate_desc>Efron correction for ties. Placebo is reference. Results typically quoted as efficacy = 100*(1-HR)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 1 or Higher Creatinine Toxicity</title>
        <description>Creatinine which reach grade 1 (mild, 1.1 to 1.3 local upper limit of normal) or higher by the US Division of AIDS grading table (version 1) or a 50% increase in creatinine from the baseline value. The DAIDS table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
        <time_frame>Duration of follow-up, median 1.2 years</time_frame>
        <population>All randomized participants which at least 1 follow-up creatinine value</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 1 or Higher Creatinine Toxicity</title>
          <description>Creatinine which reach grade 1 (mild, 1.1 to 1.3 local upper limit of normal) or higher by the US Division of AIDS grading table (version 1) or a 50% increase in creatinine from the baseline value. The DAIDS table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
          <population>All randomized participants which at least 1 follow-up creatinine value</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1216"/>
                <count group_id="O2" value="1217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <p_value_desc>p-value is not adjusted for multiple comparisons, a priori threshold for statistical significance was p &lt; 0.05</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
            <other_analysis_desc>Extensive analysis and methods published in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966916/</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 3 or Higher Phosphorous Toxicity</title>
        <description>Grade 3 or higher phosphorous toxicity (hypophosphatemia) by the Division of AIDS Grading Table (severe, level at or below 1.9 mg/dL)</description>
        <time_frame>The entire follow-up period, median 1.2 years</time_frame>
        <population>All participants with at least 1 follow-up phosphorus value</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3 or Higher Phosphorous Toxicity</title>
          <description>Grade 3 or higher phosphorous toxicity (hypophosphatemia) by the Division of AIDS Grading Table (severe, level at or below 1.9 mg/dL)</description>
          <population>All participants with at least 1 follow-up phosphorus value</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1225"/>
                <count group_id="O2" value="1226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.57</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 2, 3, or 4 Laboratory Adverse Events</title>
        <description>Number of participants with at least one Grade 2, 3, or 4 laboratory adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
        <time_frame>Entire follow-up, median 1.2 years</time_frame>
        <population>At participants with at least one visit with laboratory values post-baseline</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 2, 3, or 4 Laboratory Adverse Events</title>
          <description>Number of participants with at least one Grade 2, 3, or 4 laboratory adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
          <population>At participants with at least one visit with laboratory values post-baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1229"/>
                <count group_id="O2" value="1226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 2, 3, or 4 Clinical Adverse Events</title>
        <description>Number of participants with at least 1 Grade 2, 3, or 4 clinical adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
        <time_frame>Entire follow-up, median 1.2 years</time_frame>
        <population>At participants with at least one follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 2, 3, or 4 Clinical Adverse Events</title>
          <description>Number of participants with at least 1 Grade 2, 3, or 4 clinical adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</description>
          <population>At participants with at least one follow-up visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1226"/>
                <count group_id="O2" value="1230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis Flares Among Hepatitis B Virus (HBV) Infected Persons During and After Chemoprophylaxis</title>
        <description>A hepatic flare is defined as an increase in alanine transaminase or aspartate transaminase to &gt;5 fold upper limit of normal at any visit, or an increase to &gt;2.5 fold upper limit of normal for 3 months, within 24 weeks of permanently stopping study drug.
More details in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752387/</description>
        <time_frame>Quarterly lab tests through a median follow-up of 1.2 years</time_frame>
        <population>Those with chronic active hepatitis B at enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis Flares Among Hepatitis B Virus (HBV) Infected Persons During and After Chemoprophylaxis</title>
          <description>A hepatic flare is defined as an increase in alanine transaminase or aspartate transaminase to &gt;5 fold upper limit of normal at any visit, or an increase to &gt;2.5 fold upper limit of normal for 3 months, within 24 weeks of permanently stopping study drug.
More details in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752387/</description>
          <population>Those with chronic active hepatitis B at enrollment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Desc</non_inferiority_desc>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.00</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Bone Mineral Density</title>
        <description>% Change from baseline in bone mineral density (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in in hip and L1-L4 spine by dual-energy x-ray absorptiometry</description>
        <time_frame>baseline and week 24.</time_frame>
        <population>Participants confirmed to be HIV negative at enrollment who consented to participate in the metabolic substudy. Full details in https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25908682/</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Bone Mineral Density</title>
          <description>% Change from baseline in bone mineral density (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in in hip and L1-L4 spine by dual-energy x-ray absorptiometry</description>
          <population>Participants confirmed to be HIV negative at enrollment who consented to participate in the metabolic substudy. Full details in https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25908682/</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>L1-L4 Spine bone mineral density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.21"/>
                    <measurement group_id="O2" value="0.32" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip bone mineral density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.16"/>
                    <measurement group_id="O2" value="0.29" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>&lt; 0.05 for statistical significance. no adjustment for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-.91</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Body Fat</title>
        <description>Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Body Fat from Baseline by dual-energy x-ray absorptiometry</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>All participants in the body composition substudy who made a week 24 body scan</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Body Fat</title>
          <description>Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Body Fat from Baseline by dual-energy x-ray absorptiometry</description>
          <population>All participants in the body composition substudy who made a week 24 body scan</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.0"/>
                    <measurement group_id="O2" value="3.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>median regression</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>-0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Fasting Triglycerides</title>
        <description>Percentage Change (Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Triglycerides from Baseline from a fasting sample.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>All participants in the metabolic substudy with a week 24 fast triglyceride value</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Fasting Triglycerides</title>
          <description>Percentage Change (Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Triglycerides from Baseline from a fasting sample.</description>
          <population>All participants in the metabolic substudy with a week 24 fast triglyceride value</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.3"/>
                    <measurement group_id="O2" value="0.0" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>median regression</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol</title>
        <description>Percent change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in fasting total cholesterol from baseline</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>All participants in the metabolic substudy with a week 24 fasting cholesterol</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol</title>
          <description>Percent change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in fasting total cholesterol from baseline</description>
          <population>All participants in the metabolic substudy with a week 24 fasting cholesterol</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.2"/>
                    <measurement group_id="O2" value="-1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>median regression</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Load Among HIV Infected Participants</title>
        <description>HIV-RNA in log10 units among HIV infected participants at the time closest to HIV detection</description>
        <time_frame>At the time closest to HIV detection</time_frame>
        <population>All HIV infections detected during the study including prior to, during and after study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load Among HIV Infected Participants</title>
          <description>HIV-RNA in log10 units among HIV infected participants at the time closest to HIV detection</description>
          <population>All HIV infections detected during the study including prior to, during and after study treatment</population>
          <units>log RNA copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.11"/>
                    <measurement group_id="O2" value="5.1" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.18</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Among HIV Infected Participants Drug Resistance</title>
        <description>Genotypic resistance by clinical assays among the seroconverters from baseline to the end of the study treatment period</description>
        <time_frame>at the time of HIV acquisition</time_frame>
        <population>There were 2 TDF/FTC seroconversions at enrollment and 48 during follow-up. There were 8 Placebo seroconversions at enrollment and 83 during follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>Among HIV Infected Participants Drug Resistance</title>
          <description>Genotypic resistance by clinical assays among the seroconverters from baseline to the end of the study treatment period</description>
          <population>There were 2 TDF/FTC seroconversions at enrollment and 48 during follow-up. There were 8 Placebo seroconversions at enrollment and 83 during follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infected at Enrollment (prior to randomization)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infected after Randomization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is the proportion of mutations is identical.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>Detailed resistance data is found at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176446/</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Count Among HIV Infected Participants</title>
        <description>CD4 cell count for HIV infected participants during the trial</description>
        <time_frame>at the time infection was detected</time_frame>
        <population>HIV infected participants during the trial including those HIV+ at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count Among HIV Infected Participants</title>
          <description>CD4 cell count for HIV infected participants during the trial</description>
          <population>HIV infected participants during the trial including those HIV+ at baseline</population>
          <units>cells per cubic mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495" lower_limit="470" upper_limit="520"/>
                    <measurement group_id="O2" value="502" lower_limit="483" upper_limit="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69</ci_lower_limit>
            <ci_upper_limit>54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Missed Doses by Pill Count</title>
        <description>Estimated proportion of missed doses by pill count (assuming pills taken in unreturned bottles)</description>
        <time_frame>At 24 weeks</time_frame>
        <population>Those who bottles returned at the week 24 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Missed Doses by Pill Count</title>
          <description>Estimated proportion of missed doses by pill count (assuming pills taken in unreturned bottles)</description>
          <population>Those who bottles returned at the week 24 visit.</population>
          <units>proportion of pills not returned</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.91" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.92" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is equal proportion of pills returned</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Missed Doses by Estimate During CASI Interview</title>
        <description>Percentage of missed doses by estimate during computer assisted structured interview</description>
        <time_frame>Week 24</time_frame>
        <population>All participants who answered the adherence question with an estimated adherence on the week 24 computer assisted structured interview</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Missed Doses by Estimate During CASI Interview</title>
          <description>Percentage of missed doses by estimate during computer assisted structured interview</description>
          <population>All participants who answered the adherence question with an estimated adherence on the week 24 computer assisted structured interview</population>
          <units>percentage of doses taken</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="884"/>
                <count group_id="O2" value="902"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" spread="0.5"/>
                    <measurement group_id="O2" value="91.2" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <other_analysis_desc>Detailed methods and results are available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110718/</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Condomless Sexual Partners With HIV Positive or Unknown Status</title>
        <description>Participants self-report of the number of sexual partners with HIV positive or unknown status in the previous 12 weeks with whom they had condomless anal sex</description>
        <time_frame>At 24 weeks</time_frame>
        <population>Participants interviewed about sexual practices at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Condomless Sexual Partners With HIV Positive or Unknown Status</title>
          <description>Participants self-report of the number of sexual partners with HIV positive or unknown status in the previous 12 weeks with whom they had condomless anal sex</description>
          <population>Participants interviewed about sexual practices at week 24</population>
          <units>count</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1091"/>
                <count group_id="O2" value="1114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <p_value_desc>Not adjusted for multiple comparisons and the a priori threshold for statistical significance was p &lt; 0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Sexual Partners</title>
        <description>Self-reported total number of sexual partners in the previous 12 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <population>Participants interviewed about sexual practices at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Sexual Partners</title>
          <description>Self-reported total number of sexual partners in the previous 12 weeks.</description>
          <population>Participants interviewed about sexual practices at week 24</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1091"/>
                <count group_id="O2" value="1114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>Not adjusted for multiple comparisons, a priori threshold for statistical significance, p &lt; 0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.42</ci_lower_limit>
            <ci_upper_limit>.42</ci_upper_limit>
            <other_analysis_desc>Full details available in the methods section of https://www.ncbi.nlm.nih.gov/pubmed/24367497</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status.</title>
        <description>Self-reported condomless receptive anal intercourse in the previous 12 weeks with any partners regardless of status.</description>
        <time_frame>At 24 weeks</time_frame>
        <population>Participants interviewed about sexual practices at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status.</title>
          <description>Self-reported condomless receptive anal intercourse in the previous 12 weeks with any partners regardless of status.</description>
          <population>Participants interviewed about sexual practices at week 24</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1091"/>
                <count group_id="O2" value="1114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null is no difference between arms</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>0.030</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Confirmed Syphilis During Follow-Up</title>
        <description>Number of participants who have at least 1 confirmed syphilis infection during the study</description>
        <time_frame>All Follow-Up median of 1.2 years of follow-up</time_frame>
        <population>Participants without active syphilis at baseline with a follow-up syphilis test.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Confirmed Syphilis During Follow-Up</title>
          <description>Number of participants who have at least 1 confirmed syphilis infection during the study</description>
          <population>Participants without active syphilis at baseline with a follow-up syphilis test.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1155"/>
                <count group_id="O2" value="1171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between the arms</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of HSV-2 During the Follow-up Period</title>
        <description>Incidence of HSV-2 during the follow-up period among those HIV-2 negative at baseline</description>
        <time_frame>Total study follow-up, a median of 1.2 years</time_frame>
        <population>All HSV-2 negative participants with a follow-up HSV-2 test.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HSV-2 During the Follow-up Period</title>
          <description>Incidence of HSV-2 during the follow-up period among those HIV-2 negative at baseline</description>
          <population>All HSV-2 negative participants with a follow-up HSV-2 test.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="671"/>
                <count group_id="O2" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <other_analysis_desc>Details in the manuscript https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956614/</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnosis of Gonorrhea During the Follow-up Period</title>
        <description>Diagnosis of gonorrhea during the follow-up period by PCR</description>
        <time_frame>All of follow-up period, median of 1.2 years</time_frame>
        <population>All participants with at least one follow-up test for gonorrhea</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC</title>
            <description>Daily oral emtricitabine/tenofovir disoproxil fumarate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnosis of Gonorrhea During the Follow-up Period</title>
          <description>Diagnosis of gonorrhea during the follow-up period by PCR</description>
          <population>All participants with at least one follow-up test for gonorrhea</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1226"/>
                <count group_id="O2" value="1229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Monthly follow-up with quarterly lab assessments though a median of 1.2 years of follow-up</time_frame>
      <desc>Adverse events graded by the NIH Division of AIDS grading tables, version 1.0</desc>
      <group_list>
        <group group_id="E1">
          <title>TDF/FTC</title>
          <description>Daily oral emtricitabine/tenofovir disoproxil fumarate
Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Daily oral placebo
Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="1226"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CREATININE INCREASE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1226"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>ALT INCREASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1226"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1226"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OTHER EVENTS</sub_title>
                <description>EVENTS AFFECTING LESS THAN A TOTAL OF 5 PARTICIPANTS</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="1226"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1226"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1226"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1226"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1226"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1226"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>SUICIDAL DEPRESSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1226"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1226"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="906" subjects_at_risk="1226"/>
                <counts group_id="E2" subjects_affected="937" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PARASITIC INFECTION INTESTINAL</sub_title>
                <counts group_id="E1" events="231" subjects_affected="231" subjects_at_risk="1226"/>
                <counts group_id="E2" events="216" subjects_affected="216" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="109" subjects_affected="109" subjects_at_risk="1226"/>
                <counts group_id="E2" events="123" subjects_affected="123" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" events="82" subjects_affected="82" subjects_at_risk="1226"/>
                <counts group_id="E2" events="71" subjects_affected="71" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="73" subjects_affected="73" subjects_at_risk="1226"/>
                <counts group_id="E2" events="76" subjects_affected="76" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>SECONDARY SYPHILIS</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="1226"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>BLOOD AMYLASE INCREASED</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="1226"/>
                <counts group_id="E2" events="57" subjects_affected="57" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="151" subjects_affected="151" subjects_at_risk="1226"/>
                <counts group_id="E2" events="155" subjects_affected="155" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>BILIRUBIN INCREASE</sub_title>
                <counts group_id="E1" events="127" subjects_affected="127" subjects_at_risk="1226"/>
                <counts group_id="E2" events="132" subjects_affected="132" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" events="109" subjects_affected="109" subjects_at_risk="1226"/>
                <counts group_id="E2" events="123" subjects_affected="123" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS DECREASED</sub_title>
                <counts group_id="E1" events="122" subjects_affected="122" subjects_at_risk="1226"/>
                <counts group_id="E2" events="100" subjects_affected="100" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="1226"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="1226"/>
                <counts group_id="E2" events="87" subjects_affected="87" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="102" subjects_affected="102" subjects_at_risk="1226"/>
                <counts group_id="E2" events="107" subjects_affected="107" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="1226"/>
                <counts group_id="E2" events="84" subjects_affected="84" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URETHRITIS</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="1226"/>
                <counts group_id="E2" events="102" subjects_affected="102" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="248" subjects_affected="248" subjects_at_risk="1226"/>
                <counts group_id="E2" events="282" subjects_affected="282" subjects_at_risk="1230"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="98" subjects_affected="98" subjects_at_risk="1226"/>
                <counts group_id="E2" events="92" subjects_affected="92" subjects_at_risk="1230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Glidden</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-514-8009</phone>
      <email>david.glidden@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

